The legal landscape surrounding Depo-Provera, a long-acting injectable birth control, has entered a pivotal phase. With the growing number of lawsuits alleging that the drug caused serious brain tumors known as meningiomas, the federal judiciary has consolidated these cases into a Multidistrict Litigation (MDL). This development not only streamlines the process for affected individuals seeking justice but also signifies the growing concern over the drug's long-term safety risks.
In this article, our attorneys explain what the MDL means, how it is progressing, and what steps affected individuals can take to protect their rights.
What Is the Basis for the Depo-Provera Lawsuits?
Depo-Provera (medroxyprogesterone acetate) has been widely used for decades as a hormonal contraceptive. However, mounting research, including several European studies and adverse event reports, has pointed to a troubling association: prolonged use of Depo-Provera may significantly increase the risk of developing intracranial meningiomas, which are typically benign but potentially life-altering brain tumors.
As detailed in our recent blog, Can Birth Control Injections Cause a Meningioma? The Science Behind the Lawsuits, studies show that high doses of progestins may stimulate the growth of existing meningiomas or even contribute to their formation. Lawsuits allege that Pfizer, the manufacturer of Depo-Provera, failed to provide adequate warnings about these serious and long-term risks.
Formation of the MDL: A Turning Point in the Litigation
In response to the growing number of federal lawsuits filed across the country, the U.S. Judicial Panel on Multidistrict Litigation (JPML) formally consolidated these claims into MDL No. 3140 on February 7, 2025, in the Northern District of Florida, under Judge M. Casey Rodgers.
This decision came as more than two dozen cases filed in various states shared nearly identical allegations: that Depo-Provera users were diagnosed with meningiomas and were never warned of the risks. The MDL now centralizes these claims, allowing for coordinated discovery, consistent rulings, and more efficient management of pretrial motions. As we have previously explained, MDLs are not class actions — each plaintiff retains their own case — but they help courts handle large numbers of similar claims in a unified and fair manner.
MDL 3140: Where Things Stand Now
Since its formation, the Depo-Provera MDL has continued to grow. As of April 2025, over 130 cases have been filed into the MDL, and legal experts anticipate that number will increase significantly in the coming months. Here are key developments so far:
1. Case Management Orders Issued
Judge Rodgers has issued several critical case management directives. Notably, Pretrial Order No. 10 allows plaintiffs to file directly into the MDL, streamlining the litigation process for those joining from around the country. Meanwhile, Case Management Order No. 2 requires certain companies named in the lawsuits, such as Greenstone and Viatris, to submit sworn affidavits detailing their role — or lack thereof— in the marketing or distribution of Depo-Provera. The court has emphasized strict compliance with these orders to maintain the integrity and efficiency of the litigation process.
2. Selection of Pilot Cases
To help guide the future of the litigation, Judge Rodgers selected five pilot cases to proceed through early discovery and trial preparation. While not officially designated as bellwether trials, these pilot cases are intended to serve a similar purpose — providing insight into key legal and factual issues, and offering both sides an opportunity to evaluate how juries might respond. The outcomes may influence broader litigation strategy and settlement discussions, though they will not be binding on other cases in the MDL.
3. Leadership Structure for Plaintiffs
A Plaintiffs’ Steering Committee has been appointed to represent the interests of all plaintiffs in the MDL. This group coordinates discovery, negotiates procedural matters, and helps develop trial strategy on behalf of all participating plaintiffs. Additionally, the court has appointed Judge David Herndon (Ret.) as Special Master to help facilitate the MDL’s efficient administration, mediate disputes, and support judicial oversight.
What This Means for Individuals Affected by Depo-Provera
The MDL’s formation makes it easier and faster for injured individuals to pursue legal claims without sacrificing the unique facts of their personal situation. However, it also means that time is of the essence. The court’s schedule is moving forward quickly, and failure to act soon could limit your ability to participate.
Many individuals may not be aware of the potential link between Depo-Provera and their diagnosis. Common symptoms include:
- Chronic headaches
- Blurred or double vision
- Hearing loss or ringing in the ears
- Seizures
- Memory problems
If you’ve experienced any of these symptoms and have used Depo-Provera, it is essential to seek medical evaluation and legal advice.
Can You File a Claim?
We have previously asked (and answered) this question in our article, Can You File a Claim? Understanding Eligibility for Depo-Provera Meningioma Lawsuits. The basic eligibility criteria includes:
- Documented use of Depo-Provera, particularly over an extended period
- Diagnosis of intracranial meningioma
- Medical documentation linking the timeline of use to diagnosis
Even if you're unsure about your eligibility, speaking with an attorney can help clarify your options. Our team will guide you through every step.
Our Commitment to You
At Morris James, we are closely monitoring these developments and are committed to advocating for women harmed by taking Depo-Provera. The formation of this MDL is a significant step toward justice, but navigating it requires legal guidance and personalized support.
A meningioma diagnosis can be overwhelming, especially after years of trusting a medication you believed was safe. We are here to answer questions, offer support, and provide you with the legal representation you need.
